Published in J Neurol on December 01, 1999
The modern pre-levodopa era of Parkinson's disease: insights into motor complications from sub-Saharan Africa. Brain (2014) 1.74
Maladaptive striatal plasticity in L-DOPA-induced dyskinesia. Prog Brain Res (2010) 1.23
Aberrant restoration of spines and their synapses in L-DOPA-induced dyskinesia: involvement of corticostriatal but not thalamostriatal synapses. J Neurosci (2013) 1.06
Evaluation of levodopa dose and magnitude of dopamine depletion as risk factors for levodopa-induced dyskinesia in a rat model of Parkinson's disease. J Pharmacol Exp Ther (2007) 1.05
Evaluation of the D3 dopamine receptor selective antagonist PG01037 on L-dopa-dependent abnormal involuntary movements in rats. Neuropharmacology (2009) 0.98
Gender effect on time to levodopa-induced dyskinesias. J Neurol (2011) 0.85
Objective measurement of dyskinesia in Parkinson's disease using a force plate. Mov Disord (2010) 0.85
Motor and nonmotor complications in Parkinson's disease: an argument for continuous drug delivery? J Neural Transm (Vienna) (2013) 0.84
Motor fluctuations and dyskinesias in advanced/end stage Parkinson's disease: a study from a population of brain donors. J Neural Transm (Vienna) (2006) 0.83
Drug-induced dyskinesia in Parkinson's disease. Should success in clinical management be a function of improvement of motor repertoire rather than amplitude of dyskinesia? BMC Med (2013) 0.82
The "brittle response" to Parkinson's disease medications: characterization and response to deep brain stimulation. PLoS One (2014) 0.78
Dysregulation of BET proteins in levodopa-induced dyskinesia. Neurobiol Dis (2017) 0.75
Improving symptom control in early Parkinson's disease. Ther Adv Neurol Disord (2009) 0.75
Levodopa responsive hemidystonia associated with contralateral nigral lesion. J Neurol (2010) 0.75
Quantitative motor assessment of dyskinesias in Parkinson's disease. J Neural Transm (Vienna) (2015) 0.75
The impact of early versus late levodopa administration. J Neural Transm (Vienna) (2016) 0.75
TAP, the human homolog of Mex67p, mediates CTE-dependent RNA export from the nucleus. Mol Cell (1998) 5.85
Identification of novel import and export signals of human TAP, the protein that binds to the constitutive transport element of the type D retrovirus mRNAs. Mol Cell Biol (1999) 2.09
Elements distinct from human immunodeficiency virus type 1 splice sites are responsible for the Rev dependence of env mRNA. J Virol (1994) 1.88
Characterization and structural analysis of the laccase I gene from the newly isolated ligninolytic basidiomycete PM1 (CECT 2971). Appl Environ Microbiol (1993) 1.75
Clinical genetics of familial progressive supranuclear palsy. Brain (1999) 0.95
Quality of life in patients with Parkinson's disease who transfer from standard levodopa to Sinemet CR: the STAR Study. The STAR Multicenter Study Group. J Neurol (1998) 0.83
[Diagnosis of transmissible spongiform encephalopathies in Spain. Population perspective]. Neurologia (1999) 0.81
Acute effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in a model of rat designated a poor metabolizer of debrisoquine. J Neurochem (1991) 0.81
[Neurological complications of Mediterranean boutonneuse fever. Presentation of a case of acute encephalomeningomyelitis and review of the literature]. Neurologia (1999) 0.80
Effects of calcium antagonists on the dopamine system. Clin Neuropharmacol (1995) 0.78
[Side effects of antithrombotic treatment in the secondary prevention of cerebrovascular disease]. Rev Neurol (2000) 0.76
Premorbid dietetic habits and risk for Parkinson's disease. Parkinsonism Relat Disord (1997) 0.75
[The effect of calcium channel blockers on myoclonus induced by DDT]. Arch Neurobiol (Madr) (1991) 0.75
[Effect of a controlled low-protein diet on the pharmacological response to levodopa and on the plasma levels of L-dopa and amino acids in patients with Parkinson's disease]. Arch Neurobiol (Madr) (1992) 0.75
Changes induced by ovariectomy on the acute effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in a model of rat poor metabolizer of debrisoquine. Parkinsonism Relat Disord (1996) 0.75
[Pramipexol: a new dopaminergic agonist for the treatment of Parkinson disease]. Neurologia (1999) 0.75